Aadi Bioscience News Today

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...

HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.73) […]

Aadi Bioscience (NASDAQ:AADI – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Aadi Bioscience to post earnings of ($0.66) per share for the quarter. Aadi Bioscience (NASDAQ:AADI – Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. […]

Aadi Bioscience (NASDAQ:AADI – Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Aadi Bioscience (NASDAQ:AADI – Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The […]

Aadi Bioscience (NASDAQ:AADI – Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Aadi Bioscience (NASDAQ:AADI – Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The […]

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for...

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,100,000 shares, a growth of 16.6% from the March 31st total of 943,100 shares. Approximately 6.3% of the shares of the stock are short sold. Based […]

Biodexa’s worldwide rights of eRapa come with a $17m grant from CPRIT to support the asset into Phase III clinical trials.

Aadi Bioscience (NASDAQ:AADI – Get Free Report) and Statera Biopharma (NASDAQ:STAB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings. Profitability This table compares Aadi Bioscience and […]

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 17,772 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $2.31, for a total value of $41,053.32. Following the completion of the sale, the chairman now directly owns 1,393,771 shares of […]